Cerebrovascular DiseaseRecent advances in stroke therapyGoldszmidt, Adrian; Wityk, Robert J.aAuthor Information Division of Neurology, Department of Medicine, Sinai Hospital of Baltimore and aDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Correspondence to Robert J. Wityk MD, Johns Hopkins Hospital, Pathology 516, 600 North Wolfe Street, Baltimore, MD 21287, USA Abbreviations; ECASS: European Cooperative Acute Stroke Study; LMWH: low molecular weight heparin; MAST: Multicentre Acute Stroke Trial; NINDS: National Institutes of Neurologic Disease and Stroke; rtPA: recombinant tissue‐type plasminogen activator; tPA: tissue plasminogen activator; Current Opinion in Neurology: February 1998 - Volume 11 - Issue 1 - p 57-64 Buy Abstract Advances in stroke therapy have followed diverse paths over the past 2 years. Recent clinical trials have investigated the use of thrombolytic agents, anticoagulants, antiplatelet drugs and neuroprotective agents in acute stroke patients. The positive results of the National Institutes of Neurologic Disease and Stroke tissue plasminogen activator trial have increased interest in the field of acute stroke therapy and initiated significant changes in the management of stroke patients in the medical system. A new antiplatelet drug and a number of trials involving HMG Co‐A reductase inhibitors are important advances in the secondary prevention of stroke. Curr Opin Neurol 11:57–64. © 1998 Rapid Science Ltd © Lippincott-Raven Publishers.